 Connection
Search Results to
This is a "connection" page, showing the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
| Property | Value |
|
has minor subject area list
|
ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 CYP2C9; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Pharmacogenetics; Rosuvastatin Calcium; Simvastatin
|
|
information resource reference
|
Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 05; 111(5):1007-1021.
|
|
label
|
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
|
|
|